News | March 21, 2019
Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, achieved a fourth milestone under its license & collaboration agreement with Sanofi, triggering an...
News | February 27, 2019
The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson is...
News | March 2, 2019
UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American...
News | April 24, 2019
Skyrizi™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In clinical...
News | April 25, 2019
The FDA has approved Ortho Dermatologics' New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, indicated for the topical treatment of plaque psoriasis in adults. Duobrii is the only topical...
DermWire TV: AbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
Lead Pharma Begins Phase I Trials with SAR441169 Candidate Treatment for Psoriasis
This is dedicated to our friends in pharma…and you know who you are.
Neal Bhatia, MD, FAAD
Complaints and concerns abound, but remedies are slow in coming.
Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2019 Aspire Higher Scholarship Program
Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Study